|
|
MAS-1 |
|
Vaxjo ID |
173 |
|
Vaccine Adjuvant Name |
MAS-1 |
|
Adjuvant VO ID |
VO_0005471
|
|
Description |
A vaccine adjuvant 30:70 (w/w) Water-in-Oil (W/O) emulsion that stimulates a mixed Th1/Th2 response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
US (MerciaPharma) |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
Proprietary oily vehicle comprised of 2 metabolizable oils and 2 surfactants (all components are plant-derived, TSE-free sources |
|
Storage |
Bulk-manufactured emulsion: stable for at least 3 years (2-8Deg C), shelf life - 3 years approved by FDA for clinical trial purposes POU formulated MAS-1 emulsion: chemically stable up to 1 wk at RT during validation studies. To ensure aseptic integrity, POU MAS-1 emulsion should be used within 4hrs (clinical use) or 6 hrs (preclinical use) at RT. Sterile MAS-1 oily vehicle: stable for at least 5 yrs (RT). Shelf life of 5yrs approved by FDA for clinical trial purposes |
|
Function |
adjuvanted antigen depot at injection site |
| References |
(Blackburn, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=68]
Gorse et al., 2022: Gorse GJ, Grimes S, Buck H, Mulla H, White P, Hill H, May J, Frey SE, Blackburn P. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Vaccine. 2022; 40(10); 1472-1482. [PubMed: 35125224].
Gorse et al., 2022: Gorse GJ, Grimes S, Buck H, Mulla H, White P, Hill H, May J, Frey SE, Blackburn P. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system. Vaccine. 2022; 40(9); 1271-1281. [PubMed: 35125219].
|
|
